Legal disputes settled
Several leading pharma companies have reached agreements on outstanding legal disputes.
Several leading pharma companies have reached agreements on outstanding legal disputes.
Ranbaxy Laboratories has settled all matters relating to possible patent litigation with G1axoSmithKline regarding the sumatriptan succinate tablets, used for treating migraine, the generic version of G1axoSmithKline's Imitrex Tablets.
Terms of the settlement provide that Ranbaxy may distribute a generic version of sumatriptan succinate tablets in multiple strengths of 25mg, 50mg and 100mg in the US.
Dr Reddy's Laboratories has agreed with Novartis Pharma regarding the dismissal of the lawsuits in the US relating to the Abbreviated New Drug Applications (ANDA) filed by DRL for a generic version of rivastigmine tartrate capsules sold under the trade-name Exelon.
Under the terms of the agreement, DRL would not launch its generic rivastigmine tartrate capsules until some time before the expiry of the Orange Book patents claiming Rivastigmine.